A New York Times profile examines how former Texas Governor and U.S. Energy Secretary Rick Perry became a leading advocate for research into ibogaine, a psychoactive compound being studied for its potential therapeutic applications. The article explores the experiences and conversations that led Perry to reconsider long-held assumptions about psychedelic substances and to publicly support further scientific investigation.
The piece also looks at Perry’s role in promoting efforts to expand ibogaine research in the United States, including initiatives aimed at studying its potential use in treating addiction, trauma, and neurological injury. Through interviews and reporting, the article traces how Perry’s advocacy has helped bring greater national attention to the emerging field of psychedelic medicine.